Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Combination of anti-angiogenic molecular targeted therapy and anti- programmed cell death -1
immune checkpoint inhibitor (ICI) therapy has shown promising antitumor activity in multiple
cancer types, including patients with advanced hepatocellular carcinoma (HCC). The safety
profile and optimal dosage of targeted therapy should be carefully evaluated by clinical
trials. Regorafenib is one of the standard second-line systemic therapy for advanced HCC. The
present study will test the safety and efficacy of combination of regorafenib and
tislelizumab, an anti-programmed cell death-1 ICI. The investigator(s) thus hypothesized that
combination of tislelizumab and regorafenib is a tolerable regimen and may improve treatment
efficacy for patients with advanced HCC. The present study will explore safety and efficacy
of the combination of tislelizumab plus regorafenib as first-line therapy for advanced HCC.
Phase:
Phase 2
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborator:
National Taiwan University Hospital, Yun-Lin Branch